By Cindy Dubin, Contributing Editor
Competition has picked up in the rare disease market, which is now worth about $10 billion annually. Russell Basser, senior VP of global clinical research and development at CSL Behring, reflects, "The rare disease space is becoming so crowded. We all have to be that much smarter about how we do business, and it puts more pressure on drug development."
By Thomas Vihtelic, DVM, Ph.D., MPI Research
Opportunities abound for new treatments for inflammatory diseases, which afflict millions of people. Upward spiraling development costs, however, impede progress and delay relief for patients suffering from such debilitating diseases.
By Abhijit Gokhale and Praba Sundararajan, Pharmaceutical Development Services, Patheon Pharmaceuticals Inc.
Oral disintegrating tablets (ODTs) are designed to disintegrate rapidly in the mouth upon contact with saliva (≤ 30 seconds) and allow oral drug delivery without chewing or a need for water.
By Claudia M. Huether-Franken, Anne Niehus, and Sebastian Kleebank
Single-use bioreactor solutions have been successfully established in animal and human cell culture in the past years. Now this technology is going to make its way for microbial applications.
By Wayne Garafola, Sartorius Stedim North America, Inc.
Integrity testing is a nondestructive physical test to determine the presence of over-sized pores or other defects that may compromise a given filter’s retention capability.
By John Harrison, Ph.D., Scientific Consultant, CRF Health
July was a month of very mixed fortunes for Alzheimer's disease (AD) compound development. On the positive side, EnVivo Pharmaceuticals announced at the Vancouver AAIC event the positive effects of their nicotinic alpha 7 compound EVP-6124. Nutricia was also at AAIC to present the results of their investigation of Souvenaid, a medical food that has shown positive effects on memory in patients with early AD.
ISPE's guides describe good practices for pharmaceutical development and manufacturing and offer practical advice on regulatory initiatives. Find "real-world" information you need to help your company build on current best practices. Learn more.